Skip to main content

Table 3 Comparative sensitivity of two immunometric assays for detection of released CK19 in cancer cells

From: Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer

Cells/well

HT-29 cells

HCT 116 cells

Caco-2 cells

MCF-7 cells

EPISPOT ASSAY

    

   1,000

212.5 ± 32.7

(21.3%)

867.0 ± 28.4

(86.7%)

600.0 ± 56.5

(60.0%)

113.3 ± 4.7

(11.4%)

   100

19.8 ± 3.3

(19.8%)

93.0 ± 3.0

(93.0%)

67.5 ± 7.0

(67.5%)

13.5 ± 2.1

(13.5%)

   10

2.0 ± 0

(20.0%)

7.3 ± 1.8

(73.0%)

5.5 ± 0.5

(55.0%)

2.0 ± 0.7

(20.0%)

   1

0.25 ± 0.38

(25.0%)

1.0 ± 0

(100.0%)

0.4 ± 0.5

(40.0%)

0.23 ± 0.94

(23.0%)

ELISA

    

   1,000

2.1 ± 3.0

12.0 ± 9.2

16.7 ± 2.9

16.2 ± 5.2

   100

0.2 ± 0.2

1.0 ± 1.4

1.5 ± 1.8

2.6 ± 0.7

   10

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0

   1

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0

  1. EPISPOT and ELISA assays. Cells were cultured for 24 hours on nitrocellulose membranes of the Elispot plates. For the EPISPOT, values are expressed asCK19-releasing cells per well (mean ± SD of three experiments, with two wells in each experiment). Supernatants of the cultured cells were tested by the CYFRA 21-1 immunometric assay, and results are expressed as nanograms per milliliter.